REVA Expands Management Team With Key Executive Hire
February 25 2011 - 10:00AM
REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company"), which is
developing a novel bioresorbable slide and lock drug-eluting
coronary stent, called ReZolve™, is pleased to announce that
Jeffrey A. Anderson has joined the company's executive team as Vice
President of Clinical and Regulatory Affairs.
Mr. Anderson brings nearly 20 years of experience in the medical
device industry and previously served in the same capacity for the
company from 2004 to 2008. Prior to returning to REVA, he held
positions of Vice President of Regulatory & Clinical Affairs
and Vice President of Research and Development for Neomend, Inc.,
where he led the FDA PMA process for the Company's advanced
surgical-sealant products. Mr. Anderson brings a wealth of
cardiovascular experience, having worked at Abbott Vascular, Jomed,
CRS Clinical Research and Medtronic.
The addition of Mr. Anderson affirms REVA's commitment to
building a world-class organization in support of its business
objectives. "We are delighted to welcome Jeff Anderson back to REVA
to provide his leadership and guidance to our clinical programs as
we prepare for the start of the Pilot Study, as well as more
extensive clinical trials in the future," commented the Company's
Chairman and CEO, Robert Stockman.
REVA additionally announces the following activities:
REVA will file its Appendix 4E year end Preliminary Final Report
with the ASX on 28 February 2011, AEDT (or February 27, 2011 US
EST).
REVA will participate in the Bioresorbable Scaffold Symposium
featured at the Cardiovascular Research Technologies conference in
Washington, DC on 29 February 2011, AEDT (or February 28, 2011 US
EST). Dr. Greg L. Kaluza from the Skirball Center for
Cardiovascular Research, Cardiovascular Research Foundation, will
make the presentation.
A conference call with management is scheduled for 29 March
2011, AEDT (or Monday, March 28, 2011 US EDT) to discuss the
Company's financial results for the year ended December 31, 2010,
and business outlook. Robert Stockman, Chairman and CEO, will host
the call. Details on how to access the conference call will be
posted on the Company's website ahead of the call.
About REVA
REVA is a development stage medical device company focused on
the development and eventual commercialisation of its proprietary,
bioresorbable stent products. REVA's lead product, the ReZolve™
stent, combines REVA's proprietary stent design with a proprietary
polymer that is metabolised and cleared from the body. The ReZolve™
stent is designed to offer full x-ray visibility, clinically
relevant sizing and a controlled and safe resorption rate. In
addition, by early encapsulation of the stent in the artery tissue
coupled with the loss of stent structure over time, the ReZolve™
stent may reduce the incidence of late forming blood clots, or
thrombosis, a rare but serious problem associated with drug-eluting
metal stents currently on the market. REVA is in the process of
finalising the design of its ReZolve™ stent and intends to initiate
a pilot human clinical trial in the second quarter of
2011. REVA will require regulatory approval before it can
begin selling the ReZolve™ stent.
The REVA Medical, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8505
Forward-Looking Statements
This announcement contains forward-looking statements that are
based on management's beliefs, assumptions and expectations and on
information currently available to management. All statements that
address operating performance, events or developments that we
expect or anticipate will occur in the future are forward-looking
statements, including without limitation our expectations with
respect to regulatory submissions and approvals such; our
expectations with respect to our clinical trials, including
enrolment in or completion of our clinical trials; our expectations
with respect to the integrity or capabilities of our intellectual
property position; our ability to commercialize our existing
products; our ability to develop and commercialize new products;
and our estimates regarding our capital requirements and financial
performance, including profitability. Management believes that
these forward-looking statements are reasonable as and when made.
You should not place undue reliance on forward-looking statements
because they speak only as of the date when made. REVA does not
assume any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. REVA may not actually achieve the
plans, projections or expectations disclosed in forward-looking
statements, and actual results, developments or events could differ
materially from those disclosed in the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, described in "Risk Factors" in our Registration
Statement on Form S-1 declared effective by the United States
Securities and Exchange Commission (the "SEC") on November 15,
2010. We may update our risk factors from time to time in "Part II,
Item 1A. Risk Factors" in our Periodic Reports or other current
reports filed with the SEC.
CONTACT: Investor Enquiries:
United States:
Cheryl Liberatore; REVA Director, Corporate Development
+1 858 966-3045
Australia:
David Allen or Alan Taylor, Inteq Limited
+61 2 9231 3322
Media Enquiries:
Cannings Corporate Communications
Michael Mullane
+ 61 414 590 296
Reva Medical (ASX:RVA)
Historical Stock Chart
From Apr 2024 to May 2024
Reva Medical (ASX:RVA)
Historical Stock Chart
From May 2023 to May 2024